Larimar Therapeutics (LRMR) Competitors $1.78 -0.10 (-5.32%) Closing price 04:00 PM EasternExtended Trading$1.78 -0.01 (-0.28%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LRMR vs. ORGO, VALN, IMTX, MGTX, KURA, OPT, URGN, SAGE, ARVN, and MAZEShould you be buying Larimar Therapeutics stock or one of its competitors? The main competitors of Larimar Therapeutics include Organogenesis (ORGO), Valneva (VALN), Immatics (IMTX), MeiraGTx (MGTX), Kura Oncology (KURA), Opthea (OPT), UroGen Pharma (URGN), Sage Therapeutics (SAGE), Arvinas (ARVN), and Maze Therapeutics (MAZE). These companies are all part of the "pharmaceutical products" industry. Larimar Therapeutics vs. Organogenesis Valneva Immatics MeiraGTx Kura Oncology Opthea UroGen Pharma Sage Therapeutics Arvinas Maze Therapeutics Larimar Therapeutics (NASDAQ:LRMR) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, community ranking, risk and institutional ownership. Do analysts prefer LRMR or ORGO? Larimar Therapeutics currently has a consensus target price of $19.63, indicating a potential upside of 943.88%. Organogenesis has a consensus target price of $5.50, indicating a potential upside of 34.80%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Larimar Therapeutics is more favorable than Organogenesis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Larimar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10Organogenesis 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more risk and volatility, LRMR or ORGO? Larimar Therapeutics has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500. Is LRMR or ORGO more profitable? Larimar Therapeutics has a net margin of 0.00% compared to Organogenesis' net margin of -1.62%. Organogenesis' return on equity of -2.69% beat Larimar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Larimar TherapeuticsN/A -35.87% -32.37% Organogenesis -1.62%-2.69%-1.63% Does the MarketBeat Community favor LRMR or ORGO? Organogenesis received 51 more outperform votes than Larimar Therapeutics when rated by MarketBeat users. However, 71.88% of users gave Larimar Therapeutics an outperform vote while only 65.99% of users gave Organogenesis an outperform vote. CompanyUnderperformOutperformLarimar TherapeuticsOutperform Votes4671.88% Underperform Votes1828.13% OrganogenesisOutperform Votes9765.99% Underperform Votes5034.01% Which has stronger valuation and earnings, LRMR or ORGO? Organogenesis has higher revenue and earnings than Larimar Therapeutics. Organogenesis is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLarimar TherapeuticsN/AN/A-$36.95M-$1.30-1.45Organogenesis$482.04M1.07$4.95M-$0.02-204.00 Do insiders and institutionals believe in LRMR or ORGO? 91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 49.6% of Organogenesis shares are owned by institutional investors. 3.5% of Larimar Therapeutics shares are owned by insiders. Comparatively, 36.9% of Organogenesis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media prefer LRMR or ORGO? In the previous week, Organogenesis had 1 more articles in the media than Larimar Therapeutics. MarketBeat recorded 3 mentions for Organogenesis and 2 mentions for Larimar Therapeutics. Organogenesis' average media sentiment score of 0.83 beat Larimar Therapeutics' score of 0.00 indicating that Organogenesis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Organogenesis 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryOrganogenesis beats Larimar Therapeutics on 10 of the 18 factors compared between the two stocks. Remove Ads Get Larimar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LRMR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LRMR vs. The Competition Export to ExcelMetricLarimar TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$109.49M$6.27B$5.29B$7.60BDividend YieldN/A2.98%5.35%4.27%P/E Ratio-1.636.8322.2118.06Price / SalesN/A200.79362.1990.67Price / CashN/A65.6738.1534.64Price / Book1.015.646.263.95Net Income-$36.95M$140.88M$3.19B$247.18M7 Day Performance-5.05%0.22%-1.53%-0.72%1 Month Performance-34.72%-10.02%-0.58%-6.01%1 Year Performance-72.51%-17.16%4.93%-3.92% Larimar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LRMRLarimar Therapeutics3.0097 of 5 stars$1.78-5.3%$19.63+1,002.5%-73.3%$113.97MN/A-1.5530ORGOOrganogenesis4.0198 of 5 stars$4.32-4.0%$5.50+27.3%+39.7%$547.90M$482.04M-72.00950Gap DownVALNValneva1.6533 of 5 stars$6.71-7.6%$16.00+138.5%-16.4%$545.26M$169.58M-51.62700Analyst ForecastGap DownIMTXImmatics1.5667 of 5 stars$4.51-2.6%$16.67+269.5%-63.4%$538.30M$155.84M-6.83260MGTXMeiraGTx4.5408 of 5 stars$6.78-7.5%$24.50+261.4%-6.1%$534.64M$33.28M-5.60300Insider TradeGap DownHigh Trading VolumeKURAKura Oncology4.1589 of 5 stars$6.60-6.4%$25.50+286.4%-71.1%$532.98M$53.88M-2.80130Analyst ForecastGap DownOPTOpthea0.7925 of 5 stars$3.41+7.2%$1.33-60.9%-16.6%$524.84M$87,666.000.008Gap UpURGNUroGen Pharma3.4872 of 5 stars$11.06-1.3%$38.20+245.4%-24.5%$509.80M$90.40M-3.51200News CoveragePositive NewsGap DownSAGESage Therapeutics4.0983 of 5 stars$7.95-4.0%$8.81+10.8%-58.1%$488.77M$41.24M-1.21690News CoverageGap DownARVNArvinas3.703 of 5 stars$7.02-7.5%$35.50+405.7%-82.3%$482.78M$263.40M-2.53420Analyst ForecastNews CoverageGap DownHigh Trading VolumeMAZEMaze TherapeuticsN/A$11.01-3.6%$25.67+133.1%N/A$481.99M$167.50M0.00121Gap Down Remove Ads Related Companies and Tools Related Companies Organogenesis Alternatives Valneva Alternatives Immatics Alternatives MeiraGTx Alternatives Kura Oncology Alternatives Opthea Alternatives UroGen Pharma Alternatives Sage Therapeutics Alternatives Arvinas Alternatives Maze Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LRMR) was last updated on 4/10/2025 by MarketBeat.com Staff From Our Partners6 stocks could soar on DOGE AI news …Stay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredTrump’s policies mean HUGE income for investorsThanks to a Trump win… Investors have a HUGE opportunity at new income. The floodgates for U.S. oil prod...The Oxford Club | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for May 7th. Because on that day, I believe we could see a $2 Trillion shock INTO the ma...Timothy Sykes | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredThey Won’t Tell You This About GoldInflation, digital currency, and government policy are quietly eating away at your savings — and most people w...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Larimar Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Larimar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LRMR Stock Free LRMR Stock Alerts